Viloxazine

Summary

Viloxazine (CHEMBL306700) is an approved small molecule (ATC N06AX09); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX09
• Indications: 1 condition
• Chemistry: 237.29 Da · C13H19NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL306700
Name	Viloxazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5666
ATC	N06AX09
Molecular formula	C13H19NO3
Molecular weight	237.29
InChIKey	YWPHCCPCQOJSGZ-UHFFFAOYSA-N

SMILES: CCOC1=CC=CC=C1OCC2CNCCO2

IUPAC name: 2-[(2-ethoxyphenoxy)methyl]morpholine

Also known as: Viloxazin, Viloxazina, Viloxazine, VILOXAZINE, viloxazine, C10315682

Parent form; salt/anhydrous children: CHEMBL2106483

Patent coverage: 1,927 distinct patent families (8,115 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,881 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Sodium-dependent dopamine transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	6.81	Kd	155	nM	CHEMBL_ACT_171761
SLC6A3	6.81	Kd	155	nM	CHEMBL_ACT_171762
SLC6A2	6.44	AC50	361.7	nM	CHEMBL_ACT_25146480
SLC6A2	6.01	AC50	970	nM	CHEMBL_ACT_25145489
HTR2B	5.63	AC50	2343	nM	CHEMBL_ACT_25164241
ADRB2	5.12	AC50	7600	nM	CHEMBL_ACT_25123270
HTR1A	5.01	AC50	9725	nM	CHEMBL_ACT_25165504

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
depressive disorder	2	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).